About Novartis, australia & new zealand
Novartis, Australia & New Zealand: Providing Innovative Healthcare Solutions
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. With a strong presence in over 155 countries, Novartis has been at the forefront of developing innovative medicines and treatments for various diseases and conditions.
In Australia and New Zealand, Novartis has established itself as a leading provider of healthcare solutions. The company's commitment to improving patient outcomes is reflected in its extensive portfolio of products that cater to diverse therapeutic areas such as oncology, immunology, ophthalmology, neuroscience, respiratory diseases and more.
One of the key strengths of Novartis lies in its research and development capabilities. The company invests heavily in R&D to discover new treatments for unmet medical needs. In fact, Novartis spends around $9 billion annually on R&D activities globally. This investment has resulted in several breakthrough innovations that have transformed patient care across the world.
In Australia and New Zealand specifically, Novartis has made significant contributions towards advancing healthcare through its innovative products and services. For instance:
Oncology: Cancer is one of the leading causes of death worldwide. In this regard, Novartis has developed several groundbreaking therapies that have revolutionized cancer treatment options for patients across different stages of their disease journey.
One such therapy is Kymriah (tisagenlecleucel), which was approved by the Therapeutic Goods Administration (TGA) in 2018 for treating children with acute lymphoblastic leukemia (ALL). Kymriah is a CAR-T cell therapy that involves genetically modifying a patient's own immune cells to recognize and attack cancer cells.
Another notable product from Novartis' oncology portfolio is Lutathera (lutetium Lu 177 dotatate), which was approved by TGA in 2018 for treating neuroendocrine tumors (NETs). Lutathera is a targeted radioligand therapy that delivers radiation directly to tumor cells while sparing healthy tissues.
Immunology: Autoimmune diseases are characterized by an overactive immune system attacking healthy tissues within the body. To address this challenge, Novartis offers several therapies targeting specific pathways involved in autoimmune disorders such as psoriasis or rheumatoid arthritis.
Cosentyx (secukinumab) is one such therapy approved by TGA for treating moderate-to-severe plaque psoriasis since 2015; it works by blocking interleukin-17A cytokine signaling pathway responsible for inflammation associated with psoriasis symptoms like redness or scaling skin patches on elbows or knees etcetera).
Ophthalmology: Eye disorders can significantly impact quality-of-life if left untreated; hence early diagnosis & treatment are crucial here too! To help patients suffering from eye-related conditions like age-related macular degeneration or diabetic retinopathy etcetera; novatis offers innovative treatments like LucentiS®️(ranibizumab) - an anti-VEGF medication used intravitreally via injection into eyes under sterile conditions after numbing them with local anesthesia - which helps reduce vision loss due to abnormal blood vessel growth beneath retina causing fluid leakage & scarring!
Neuroscience: Neurological disorders affect millions globally every year; hence there's always need for better management options here too! To help people living with neurological conditions like multiple sclerosis or Alzheimer’s disease etcetera; novatis offers innovative treatments like Gilenya®️(fingolimod) - an oral medication used once daily - which helps reduce relapses & disability progression associated with MS!
Respiratory Diseases: Respiratory illnesses can be debilitating if not managed properly! Hence novatis offers effective medications like Ultibro Breezhaler®️(indacaterol/glycopyrronium bromide) – inhalation powder used twice daily via dry-powder inhaler device – which helps improve lung function & reduces exacerbations associated with chronic obstructive pulmonary disease(COPD).
Apart from these products mentioned above; novatis also provides other services including clinical trials support programs aimed at helping researchers develop new drugs faster than ever before possible using cutting-edge technologies available today!
Overall ,Novaris' commitment towards providing innovative healthcare solutions makes it stand out among other companies operating within this space . Its focus on research & development coupled with strong partnerships across academia , industry players , governments ensures continued success both locally within Australia/New Zealand region as well globally !
novartis.com.au
